| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
38,470,000 |
| Market
Cap: |
7.26(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.1557 - $0.2674 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Akari Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for acute and chronic inflammation, specifically through the inhibition of the complement (C5) and leukotriene pathways. Co.'s primary product candidate, nomacopan, inhibits both terminal C5 activation and leukotriene B4 (LTB4). Co.'s clinical targets for nomacopan are orphan inflammatory diseases where the inhibition of both C5 and LTB4 are implicated, including bullous pemphigoid, pediatric hematopoietic stem cell transplant-associated thrombotic microangiopathy, and as well as inflammatory conditions in the eye and lung including dry eye, dry AMD and COVID-19 pneumonia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dicicco Wendy F |
Interim CFO |
• – – |
2024-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
158,473,915 |
158,473,915 |
|
- |
|
| Jacques Rachelle Suzanne |
Chief Executive Officer |
• • – |
2024-04-26 |
4 |
A |
$0.00 |
$0 |
D/D |
479,569,892 |
1,018,027,792 |
|
- |
|
| Jacques Rachelle Suzanne |
Chief Executive Officer |
• • – |
2024-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
538,457,900 |
|
- |
|
| Patel Samir Rashmikant |
|
– • – |
2024-01-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,085,237,500 |
|
- |
|
| Grissinger Michael |
|
– • – |
2024-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20,000,000 |
|
- |
|
| Williams Donald A |
|
– • – |
2024-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20,000,000 |
|
- |
|
| Prudo Ray |
|
– • – |
2024-01-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
839,476,200 |
|
- |
|
| Prudo Ray |
|
– • – |
2024-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,147,483,647 |
|
- |
|
| Ungar Stuart |
Director |
– • • |
2015-09-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
722,345,600 |
|
- |
|
| Hill James |
Director |
– • • |
2015-09-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
722,345,600 |
|
- |
|
| Rpc Pharma Ltd |
10% Owner |
– – • |
2015-09-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
722,345,600 |
|
- |
|
| Prudo Ray |
Director |
– • • |
2015-09-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
722,345,600 |
|
- |
|
| Cohen Mark S |
Director |
– • – |
2015-09-18 |
4 |
B |
$0.19 |
$200,036 |
D/D |
1,055,600 |
1,055,600 |
2.39 |
- |
|
| Cohen Mark S |
Director |
– • – |
2015-01-08 |
4 |
OE |
$0.02 |
$3,172 |
D/D |
202,700 |
152,000 |
|
- |
|
| Shaw Allan |
Director |
– • – |
2015-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
33,530 |
|
- |
|
| Sidransky David |
Director |
– • – |
2015-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
54,732 |
|
- |
|
| Roshwalb Gur |
Chief Executive OfficerOfficer |
• • – |
2015-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
175,438 |
|
- |
|
| Cohen Mark S |
Director |
– • – |
2015-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,389,557 |
|
- |
|
18 Records found
|
1
|
Page 1 of 1 |
|
|
